Do you need a Byetta lawyer in District of Columbia? Contact one of our Byetta lawyers in District of Columbia now.
Home : Unsafe Drugs : Byetta : News Articles
Byetta - News Articles
-
Jun 2, 2008
Nurse.com, VA -
Byetta (exenatide) is used to treat T2 diabetes, and is an injectable, synthetic version of a hormone found in the saliva of the Gila monster. It is an incretin mimetic drug, which mimics the actions of naturally occurring human hormones produced by the intestines. ... -
May 7, 2008
Bloomberg -
By Dermot Doherty May 7 (Bloomberg) -- Cancer drugs have propelled Roche Holding AG's profit by more than 20 percent a year since 2004. To continue the pace, the Swiss company is racing to break into the fast-expanding, $21 billion-a-year diabetes market. ... -
May 30, 2008
TMCnet -
In terms of competitors, Bergenhem pointed to Byetta, a first-in-class incretin mimetic co-marketed by San Diego-based Amylin Pharmaceuticals Inc. and Indianapolis-based Eli Lilly and Co. "If you look at a molecule like Byetta, you see an increase in insulin ... -
May 28, 2008
Forbes, NY -
AP 05.28.08, 8:04 AM ET Activist investor Carl Icahn has taken a larger share of biotechnology company Amylin Pharmaceuticals Inc., and an analyst upgraded the stock Thursday, saying investors will focus on strategic options for Amylin. On Thursday, Icahn reported a ... -
May 24, 2008
AHN -
Copenhagen, Denmark (AHN) - Insulin was found to more effectively control blood sugar levels than pills in dealing with diabetic patients during a study. A research sponsored by Novo Nordisk A/S and Roche Holding AG and the government of China showed that ... -
May 23, 2008
Reuters -
COPENHAGEN, May 23 (Reuters) - Denmark's Novo Nordisk A/S (NOVOb.CO: Quote, Profile, Research), the world's biggest maker of insulin, has filed for regulatory approval of its experimental type 2 diabetes treatment liraglutide in the United States and Europe. ... -
May 27, 2008
CNNMoney.com -
By Anita Greil ZURICH -(Dow Jones)- An experimental Roche Holding AG (RHHBY) diabetes drug appears to be well-tolerated and effective, analysts at Zuercher Kantonalbank said Tuesday, referring to information posted on the Web site of a major meeting of diabetes experts next ... -
Jun 2, 2008
Motley Fool -
By Brian Orelli June 2, 2008 Comments (0) The one-drug wonders of the pharmaceutical world fascinate me. These companies have shown they have the stuff to get at least one successful drug to market -- not a minuscule task, especially in today's FDA environment ... -
Jun 2, 2008
Earthtimes (press release), UK -
SAN DIEGO , June 2 -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the company will present new data for its FDA-approved diabetes drugs ... -
Jun 2, 2008
ic Wales, United Kingdom -
A TOP garden designer today spoke of how his health dramatically blossomed within hours of getting a diabetes check-up, and urged other sufferers not to ignore the condition. Barry Mayled, a gold medal winner at the recent Chelsea Flower Show, said ...
-
Jun 2, 2008
Earthtimes (press release), UK -
SAN DIEGO , June 2 -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the company will present new data for its FDA-approved diabetes drugs ... -
Jun 2, 2008
ic Wales, United Kingdom -
A TOP garden designer today spoke of how his health dramatically blossomed within hours of getting a diabetes check-up, and urged other sufferers not to ignore the condition. Barry Mayled, a gold medal winner at the recent Chelsea Flower Show, said ... -
Tuesday, June 03, 2008
Barron's -
Currently, Amylin produces Byetta, the only GLP-1 analogue commercially available in the US, splitting revenues with Alkermes (ALKS) and Eli Lilly (LLY), ... -
Jun 26, 2007
Trading Markets, CA -
Study findings showed comparable improvements in blood sugar control with BYETTA and insulin glargine therapies, with weight loss and lower incidence of hypoglycemia associated with BYETTA. Patients in the study were also taking one of two commonly used oral medications. This ... -
Jun 23, 2007
FinanzNachrichten.de, Germany -
BYETTA treatment was also associated with improvements in cardiovascular risk factors in people with type 2 diabetes. These findings were presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago.People with type 2 diabetes are at increased ... -
Jun 26, 2007
Earthtimes.org -
In their study, patients with type-2 diabetes were treated with the drug exenatide (brand name Byetta) and observed for three years. Some participants were administered the injected drug and others took a placebo along with oral treatments for diabetes (metformin ... -
Jun 25, 2007
The Money Times, India -
by Keerat - June 25, 2007 - 0 comments Results of a study conducted by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. have shown that BYETTA (exenatide) injection shows comparatively better results than insulin glargine treatment in people with type 2 diabetes.The two pharmaceutical companies announced ... -
Jun 25, 2007
PR Newswire (press release), NY -
BYETTA offers added benefits of progressive weight loss and improved beta cell function in an analysis of the longest extension study to date - CHICAGO, June 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced three-year, open-label ... -
Jun 24, 2007
TheStreet.com -
Results of a Lilly-sponsored clinical trial said combining Byetta with the generic diabetes pill metformin produced a statistically significant reduced risk ... -
Wednesday, July 11, 2007
FDA news (subscription), VA -
In his blog, Ed Silverman writes that Merck’s Januvia and Eli Lilly’s Byetta, two new diabetes drugs, are no bargain. According to Silverman, they are no more effective than medications costing a few cents per pill.Silverman writes, “Research also showed the new drugs carry ...
Do you need a Byetta lawyer in District of Columbia? Contact one of our Byetta lawyers in District of Columbia now.
Pages: 1 2 3 4 5 6 ... Next
